Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
Erdafitinib for FGFR-mutated urothelial carcinoma
Emerging targets and drug developments in NSCLC
The role of immunotherapy in the radical treatment of NSCLC: where are we headed?
Case-based debate: is there evidence for local treatment in oligometastatic prostate cancer?